123 related articles for article (PubMed ID: 28612456)
1. Day 14 bone marrow examination in the management of acute myeloid leukemia.
Terry CM; Shallis RM; Estey E; Lim SH
Am J Hematol; 2017 Oct; 92(10):1079-1084. PubMed ID: 28612456
[TBL] [Abstract][Full Text] [Related]
2. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
Ofran Y
Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
[TBL] [Abstract][Full Text] [Related]
3. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
4. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
7. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
8. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
9. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
10. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
11. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.
Godwin CD; Zhou Y; Othus M; Asmuth MM; Shaw CM; Gardner KM; Wood BL; Walter RB; Estey EH
Blood; 2021 Jan; 137(4):569-572. PubMed ID: 33507294
[No Abstract] [Full Text] [Related]
13. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.
Percival ME; Lai C; Estey E; Hourigan CS
Blood Rev; 2017 Jul; 31(4):185-192. PubMed ID: 28190619
[TBL] [Abstract][Full Text] [Related]
14. Post chemotherapy blood and bone marrow regenerative changes in childhood acute lymphoblastic leukemia a prospective study.
Kushwaha R; Kumar A; Aggrawal K; Nigam N; Kumar A
Indian J Pathol Microbiol; 2014; 57(1):72-7. PubMed ID: 24739836
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients.
El Gammal MM; Owaidat HM; Rashed RA; Fatah RA; Samra MA
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e406-e413. PubMed ID: 31031147
[TBL] [Abstract][Full Text] [Related]
16. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
[TBL] [Abstract][Full Text] [Related]
17. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.
Morris TA; DeCastro CM; Diehl LF; Gockerman JP; Lagoo AS; Li Z; Moore JO; Rizzieri DA; Rao AV
Leuk Res; 2013 Jan; 37(1):28-31. PubMed ID: 23046833
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y; Leiba R; Ganzel C; Saban R; Gatt M; Ram R; Arad A; Bulvik S; Hellmann I; Gino-Moor S; Zuckerman T; Hoffman R; Horowitz N; Lavi N; Ringelstein S; Henig I; Hayun M; Rowe JM
Am J Hematol; 2015 Dec; 90(12):1159-64. PubMed ID: 26435038
[TBL] [Abstract][Full Text] [Related]
19. Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia.
Browman GP; Preisler HD
Leuk Res; 1992; 16(5):511-9. PubMed ID: 1625477
[TBL] [Abstract][Full Text] [Related]
20. New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.
Mattison RJ; Luger SM; Lazarus HM
Curr Opin Hematol; 2013 Mar; 20(2):93-9. PubMed ID: 23328452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
